102 related articles for article (PubMed ID: 25701783)
1. Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.
Refaat A; Aminullah ; Zhou Y; Kawanishi M; Tomaru R; Abdelhamed S; Shin MS; Koizumi K; Yokoyama S; Saiki I; Sakurai H
Biochem Biophys Res Commun; 2015 Mar; 458(4):856-61. PubMed ID: 25701783
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
3. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
7. Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
Gupta P; Emdad L; Lebedeva IV; Sarkar D; Dent P; Curiel DT; Settleman J; Fisher PB
J Cell Physiol; 2008 Jun; 215(3):827-36. PubMed ID: 18270968
[TBL] [Abstract][Full Text] [Related]
8. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
9. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
[TBL] [Abstract][Full Text] [Related]
12. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
15. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Fu YN; Yeh CL; Cheng HH; Yang CH; Tsai SF; Huang SF; Chen YR
Oncogene; 2008 Feb; 27(7):957-65. PubMed ID: 17653080
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
19. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]